News about Global Pharma

Lupin Receives EIR from US FDA for Pithampur Unit-1 Facility

Global pharma major Lupin Ltd. has received an EIR with a Voluntary Action Indicated (VAI) classification from the US FDA for its Pithampur Unit-1 manufacturing facility following a September 2024 inspection.

Global Pharma | 09/01/2025 | By Manvi |  608

Valo Health and Novo Nordisk to Develop Novel Treatments for Cardiometabolic Diseases

The expanded collaboration will continue to leverage the capabilities of Valo’s Opal Computational Platform, as well as key joint capabilities in human data and genetics with Novo Nordisk’s expertise in cardiometabolic diseases.

Global Pharma | 09/01/2025 | By Aishwarya |  698

Antag Therapeutics Names Dr. Joerg Moeller as its Chief Executive Officer

With over 30 years of industry and leadership experience, Dr. Moeller has an impressive track record of successfully leading large global organizations and has built an expansive portfolio by driving strategic growth, regulatory compliance, and fostering innovation.

Global Pharma | 09/01/2025 | By Aishwarya |  260

NorthStar and YAP Therapeutics to Develop and Manufacture Radiopharmaceutical Products

Within this collaboration, NorthStar will support the development of YAP Therapeutics' biologic products by supplying the radioisotope non-carrier added actinium-225 (n.c.a. Ac-225) and providing access to its radiopharmaceutical contract development and manufacturing (CDMO) services.

Global Pharma | 09/01/2025 | By Aishwarya |  626

BlackfinBio Acquires Parkinson's IP Patent Portfolio from OXB

BlackfinBio Ltd (BFB), a clinical-stage gene therapy company, has acquired the Parkinson's patent portfolio from OXB to develop as part of its BFB-201 program targeting dopamine deficiency diseases.

Global Pharma | 08/01/2025 | By Manvi |  172

Orna Therapeutics and Vertex Pharmaceuticals Partner on Next-Gen Therapies for SCD and TDT

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, has entered a three-year collaboration with Vertex Pharmaceuticals to leverage its proprietary LNP delivery technology for next-generation gene-editing therapies targeting SCD and TDT.

Global Pharma | 08/01/2025 | By Manvi |  916

ProBioGen Expands Protein and Viral Manufacturing in Berlin Plant

In the protein vertical, this strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development through to commercial manufacturing.

Global Pharma | 08/01/2025 | By Aishwarya |  326

ASPA Announces to Host Sixth Edition of TAF 2025

TAF 2025, themed ‘Path to a Secure Future – Authentication and Traceability for All’, is recognized as a premier global platform for tackling challenges related to counterfeiting, traceability, and brand protection.

Global Pharma | 08/01/2025 | By Aishwarya |  905

Phillips Medisize Expands its Inhalation Drug Delivery Capabilities

With the addition of Vectura, the company now offers a wider range of formulation, device design, combination product development and manufacturing services.

Global Pharma | 08/01/2025 | By Aishwarya |  440

Dizal's Sunvozertinib Receives FDA Priority Review for EGFR-Mutated NSCLC Treatment

Dizal's Sunvozertinib, an oral EGFR inhibitor for advanced NSCLC with EGFR exon20ins mutations, receives FDA priority review, marking a milestone in addressing unmet needs in cancer treatment.

Global Pharma | 07/01/2025 | By Manvi |  434